Navigation Links
DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Date:5/3/2012

iver sufentanil to chronic pain sufferers for a period of up to 7 days from a single application; this compares favorably against existing fentanyl patches which are substantially larger and typically effective for 2-3 days.  ELADUR, for topical neuropathic conditions such as post-herpetic neuralgia (PHN), is our proprietary transdermal patch intended to deliver bupivacaine for a period of up to three days from a single application; existing lidocaine patches for this condition can be worn for 12 hours with a rest period of 12 hours during which time many patients experience breakthrough pain.  Pfizer's termination of the ELADUR collaboration in the first quarter of 2012 returns to DURECT the rights to develop and commercialize ELADUR worldwide.  We are in discussions with potential partners regarding licensing development and commercialization rights to these two transdermal programs to which we hold worldwide rights.
  • ORADUR-ADHD Program.  We are developing a drug candidate (ORADUR-ADHD) based on DURECT's ORADUR Technology for the treatment of Attention Deficit Hyperactivity Disorder. This drug candidate is intended to provide once-a-day dosing with added tamper resistant characteristics to address common methods of abuse and misuse of these types of drugs.
    We and Orient Pharma have completed several Phase I pharmacokinetic studies with multiple formulations.  Based on information from those studies, we are continuing to evaluate our lead formulations.  Orient Pharma is our licensee for certain Asian and South Pacific countries, while we retain the rights to the rest of the world.
  • Relday™ (Risperidone Program).  In July 2011, we signed a development and license agreement with Zogenix to develop Relday, a product candidate targeting the antipsychotic market.  Zogenix expects to initiate clinical studies for Relday in patients with schizophrenia in 2012.  Relday is a proprietary
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
    2. DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call
    3. DURECT to Participate in Upcoming Healthcare Conferences
    4. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
    5. DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
    6. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
    7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
    8. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
    9. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
    10. DURECT to Present at the Jefferies Healthcare Conference
    11. DURECT Announces Resignation of Chief Medical Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
    (Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
    (Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
    Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
    ... VIVUS, Inc. (Nasdaq: VVUS ) today announced ... Drug Administration (FDA) for the New Drug Application (NDA) for ... meeting occurred on January 19th at the FDA,s offices in ... and VIVUS, management and consultants.  At this meeting the FDA ...
    ... D. Clark Turner, PhD, President and CEO of Aribex, Inc., ... in a ceremony Tuesday night at Discovery Gateway. Utah Governor ... others for providing distinguished service that has benefited the State ... be recognized among the other accomplished individuals who are receiving ...
    Cached Medicine Technology:VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3Aribex CEO Receives Utah Governor's Medal 2
    (Date:7/13/2014)... York (PRWEB) July 13, 2014 Intraocular ... Trends and Forecast 2013 - 2019 , Intraocular lens ... suffering from myopia or cataracts. The lenses are inserted ... the cataract surgery intraocular lens replaces the focusing power ... with original crystalline lens to deliver the light focusing ...
    (Date:7/13/2014)... in Nature Genetics identifies a novel ... causes eosinophillic esophagitis (EoE), opening up potential new ... allergy. , EoE is a chronic inflammatory ... by allergic hypersensitivity to certain foods and an ... called eosinophils (part of the body,s immune system). ...
    (Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
    (Date:7/13/2014)... 13, 2014 Chromatography system is ... from various types of biological samples such as ... sample mixture into two phase, namely mobile phase ... phase run over the stationary phase, followed by ... that provide the separation of mixture. Chromatography system ...
    (Date:7/13/2014)... July 13, 2014 Recently, MillionaireCasket.com, a well-known ... oak caskets . Additionally, the company’s chief executive officer ... the new oak caskets are offered at discounted prices, from ... am concerned, quality caskets are in huge demand in the ... caskets . We have a lot of high quality ...
    Breaking Medicine News(10 mins):Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2
    ... Report ... July 24 Are you an e-patient?,Studies show that ... information. Thanks to Web 2.0, e-patients now have even ... care and learn about,advanced medical technologies. Go to ...
    ... helps those with HIV who become treatment-resistant, study shows ... offers more evidence that a new AIDS drug brings ... , The drug, known as raltegravir (Isentress), almost doubles ... virus despite being immune to other medications, according to ...
    ... HTH Worldwide, a global health and,safety services ... its,CityHealth(R) Profiles to Living Abroad.com and its multi-national ... to trusted,medical care in hundreds of destinations around ... information for those living,overseas or about to be ...
    ... Health and nutrition researcher Frank,Ervolino, ND, investigated ... the risks associated with stimulants. He reports that,Appetite ... Zurich,Pharmaceuticals, makes novel use of an established ingredient ... to lose weight. In fact, in the,U.S., where ...
    ... the University of Warwick, Dartmouth College, and the University ... influenced by the weight of those around them. Without ... keep up with the weight of the Joneses. For ... of imitative obesity. The researchers will present their results ...
    ... adoption of interoperable Health Information Technology (HIT) will ... in the U.S. healthcare system," Yul D. Ejnes, MD, ... on Health today. "Unfortunately, without adequate financial incentives, ... the technological curve." Dr. Ejnes, a member of the ...
    Cached Medicine News:Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:Drug Holds Promise Against AIDS 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:New Natural Product from Zurich Pharmaceuticals Downs Appetite 2Health News:Research says fat friends and poor education helps people think thin 2Health News:ACP says Medicare should increase payments for physicians that use HIT to improve quality 2
    ... the new large power line ... function as both cordless AND ... in flexibility. Its the versatility ... with the security of the ...
    ... consists of a pistol-grip handpiece available in ... wide range of couplers that can be ... applications., ,MicroAire SmartDriver. Modular Pistol-Grip instrument ... different module for drilling, pinning, cutting, and ...
    ... Meniscus Implant (CMI) is a type I ... irreparable meniscus tear or loss of meniscus ... procedure. The purpose of the CMI ... and return to a more vigorous lifestyle, ...
    ... The MicroAire Carpal Tunnel Release System ... surgery. This innovative system, using a minimally-invasive ... small incision at the base of the ... assembly. An endoscope, connected to a standard ...
    Medicine Products: